Dividend logo

The major pharmaceutical companies are facing quite a predicament. Billions of dollars worth of patent-protected drugs have already gone or are preparing to go generic over the next few years. Dubbed the “patent cliff”, the loss of these blockbusters and other major money-making drugs for the largest pharmaceutical companies is enough to make any investor cringe. For dividend investors, it’s especially troublesome as some of these drugs have been the driving force behind Big Pharma’s status as dividend safe havens.

Rather than resignedly driving over the cliff, Big Pharma has at least begun to pump the brakes and look for alternatives. As a result, Big Pharma has found itself diving head first into biotech manufacturers and their lucrative cures for rare diseases.

Except, it turns out that biotech may not be the panacea they hoped for. Regulation and public scorn could crimp the ability of the biotechs – and correspondingly Big Pharma – to charge an arm and a leg for the medications.

To read the Full Story, Go Premium or Log In

Popular Articles

Premium Market%20performance%20charts
News

The Market Wrap For January 18: A Critical Earnings Season Begins

It’s no secret that the market’s direction has all been news-driven. The news about the trade...

News

Trending: Vodafone Dividend at Risk as Challenges Mount

Dividend.com analyzes the search patterns of our visitors each week. By sharing these trends with...

Premium Value%20stocks
News

Value Stocks Are Dirt Cheap & That’s Wonderful News For Dividend Investors

Pull up any broad chart and you’ll notice one thing. That is, the markets have been focused on ‘...